Acorn Capital Advisors, LLC

Acorn Capital Advisors, LLC reported 22 holdings worth US$364M as of Sep 30, 2026 (Form 13F)

As of Sep 30, 2026 · Filed Nov 16, 2026

Acorn Capital Advisors, LLC reported 22 holdings worth US$364M as of Sep 30, 2026. Largest: CG Oncology, Inc., Puma Biotechnology Inc and Candel Therapeutics, Inc. Filed Nov 16, 2026 (Form 13F).

Holdings
22
Value as reported
US$364M

The filing in full

CompanySharesValue as reported% of portfolio
CG Oncology, Inc.1.13MUS$80.2M22.0%
Puma Biotechnology Inc4.13MUS$41M11.3%
Candel Therapeutics, Inc.3.5MUS$36.5M10.0%
Trevi Therapeutics, Inc.2.14MUS$30.7M8.4%
Cybin, Inc.1.54MUS$18.9M5.2%
Jade Biosciences, Inc.987KUS$13.9M3.8%
Bicara Therapeutics Inc.668KUS$12.4M3.4%
Verastem, Inc.1.47MUS$11.8M3.2%
OnKure Therapeutics, Inc.2.84MUS$7.75M2.1%
AN2 Therapeutics, Inc.1.3MUS$6.92M1.9%
Aura Biosciences, Inc.1.03MUS$6.44M1.8%
Protara Therapeutics, Inc.1.75MUS$5.34M1.5%
Annexon, Inc.1.14MUS$4.81M1.3%
LeonaBio, Inc.1.14MUS$4.09M1.1%
Whitehawk Therapeutics, Inc.932KUS$3.5M0.96%
Q32 Bio Inc.216KUS$1.79M0.49%
Karyopharm Therapeutics Inc.1.22MUS$1.49M0.41%
Jasper Therapeutics, Inc.1.44MUS$834K0.23%
VYNE Therapeutics Inc.32,005US$721K0.20%

Source

Download original · View original at SEC

Related